Literature DB >> 9172085

Cost-effectiveness of the influenza vaccine in a healthy, working-age population.

D S Campbell1, M H Rumley.   

Abstract

To determine if the influenza vaccine can reduce absenteeism and the cost of Influenza-Like Illness (ILI) in healthy adults in the workplace, a prospective, non-randomized, non-placebo control trial was done in six North Carolina textile plants. One hundred thirty-one vaccinated employees were compared with 131 age- and gender-matched non-vaccines from different plants. Twenty-six (20%) of the vaccinated and 64 (49%) of the unvaccinated group had ILI (P = 0.0000008). Fifteen (11%) of the vaccinated and 31 (24%) of the unvaccinated employees missed work because of ILI (P = 0.01). There were 43 lost workdays in vaccinated and 93 in unvaccinated employees (P = 0.00004). The "cost per saved lost workday" was $22.36, for a company savings of $2.58 per dollar invested in the vaccination program. We concluded that the influenza vaccine can give significant reductions in incidence, absenteeism, and cost associated with ILJ in the workplace.

Mesh:

Substances:

Year:  1997        PMID: 9172085     DOI: 10.1097/00043764-199705000-00006

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  37 in total

1.  Coping with flu season.

Authors:  E Weir
Journal:  CMAJ       Date:  2000-03-21       Impact factor: 8.262

2.  Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective.

Authors:  S C Wood; V H Nguyen; C Schmidt
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

Review 3.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

Review 4.  Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Authors:  Maarten J Postma; Paul Jansema; Marianne L L van Genugten; Marie-Louise A Heijnen; Johannes C Jager; Lolkje T W de Jong-van den Berg
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Influenza vaccination in Alberta long-term care facilities.

Authors:  M L Russell
Journal:  CMAJ       Date:  2001-05-15       Impact factor: 8.262

6.  A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK.

Authors:  Roben Das Gupta; Julian F Guest
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 7.  Influenza and cardiovascular disease: is there a causal relationship?

Authors:  Mohammad Madjid; Ibrahim Aboshady; Imran Awan; Silvio Litovsky; S Ward Casscells
Journal:  Tex Heart Inst J       Date:  2004

8.  The influence of altruism on influenza vaccination decisions.

Authors:  Eunha Shim; Gretchen B Chapman; Jeffrey P Townsend; Alison P Galvani
Journal:  J R Soc Interface       Date:  2012-04-11       Impact factor: 4.118

9.  Mandatory influenza vaccination for health care workers as the new standard of care: a matter of patient safety and nonmaleficent practice.

Authors:  Nicolas Cortes-Penfield
Journal:  Am J Public Health       Date:  2013-12-12       Impact factor: 9.308

10.  Employer-incurred health care costs and productivity losses associated with influenza.

Authors:  Sudeep Karve; Derek A Misurski; Genevieve Meier; Keith L Davis
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.